Abivax Sa · EURONEXT:ABVX

Abivax Sa — Investor Presentation (April 2019)

22 slides from Abivax Sa's investor presentation, April 2019

  1. Slide 1: A Turning Story Towards Inflammatory Diseases

    A Turning Story Towards Inflammatory Diseases Targeting the immune system to eliminate inflammatory and viral disease as well as cancer April 2019 Oy H > abivax

  2. Slide 2: .CF F CC

    .CF F CC A 3 DF C 7C CFA C D F C 2 P 0 F CF A A F C F F 7 CF CF AD C CF F DF A F DF C CF FF DF CF AD C F 77IF 7 7CAD CF 7CFF 7 C CFA C 7C DF C CF C F CFA C F A CF A C F CF F 7 D F C F 7CAAI 7 F CF CF CFA 0 F CF A A F C F F 7 CF CF AD C CF F DF 77 D F DC F D 7 3 DF C 7C CF F CC A 3 A F 7 A A N 7IFF F

  3. Slide 3: C I D> : D II D> C A I

    , ( ) C I D> : D II D> : C A I 2B C> D - C D> C O NB O : C D I D D B CC O I B7F 0 5 B: A D D C B : B I I I I > D B F G D BD CDI I D B: I B D: O , CD A DD AB AD B BA B : > B D D D B CC O C : 41 C 4 . C> D D I D : D B: : B I I O B CDI D DF5 D D A A BCH : D C D I 32- I O D B: : B I -: 7 A 7 D D B CC O

  4. Slide 4: ABX464 colitis model data

    C B submucosa ABX464 MC 12:) ) B N C= = C 488 D 4 6 4 4 4 64 4 4 6 6 7 D C N CAB % 5 =C C D C 488 12:) ) % 12:) ) % ABX464 % MC %% .% 4 muco% submucosa % * % * % * (% (* )% )* *% ** % * % %% %% (%% )%% *%% % B %% %% (%% )%% *%% 12:) ) % 0 12:) ) % 0 6 I 0 ABX464 C gavage 10 11 3B DC 9 D 6 8 7 I 8=C

  5. Slide 5: 8N S MDB , IGDT

    8N S MDB , IGDT I F FD F I I NLIFF G FND NDI F MN S /C I C I M , ( 2 =C A :=A = =C C , ( M IA NL NG N ) M I BID B -. ( ( U 8D BF IM ) GB I 4 C B C -. ( ( U 8D BF IM ) GB I ) 5 N CD B F I I M IA C I M =C C 0 =F = = =F= = - =C F B FM) 8 A NS A= F =F= C A=F C BBIC B IA F C 61 O = A NIB : C F F =F = C F

  6. Slide 6: 4GG IG CD

    0:) ) % . 4GG IG CD 28A 6 BB 8 NC B I CG 14 8 B 4 =84B 8 A84 >8 8>8A 8 47 8AB8 DC C D C 8 8 B . ( A8 4A7=8BB 9 64 B4= 6G B G E DCA C 3 ) -% 1=4685 - G G GI C C C CG G CA C C B A C B D GI GI I E I C D C A 01 A84 >8 ( (( ) 8>8A 8 47 8AB8 8 8 B 4 IGC C D C GI I 6G ICG I - () - E C D I GEC D C I CG DD 3

  7. Slide 7: P>PF PF > FD FCF > P BCCF > > EFBRBA C

    12 / P>PF PF > FD FCF > P BCCF > > EFBRBA C I> B A F P A> + 6963 6==6:9) 0 / 3 2: BM > SB PE> ( 9 9 ( ( B0 99%7 99%7 99 3 F F > BIF F )+ %) % .94:=3: 63 6 : 9) 5 A B 5 A F FI RBIB P + % ) % 3F F > B B - % )) %)) 6963 = :9= ) P> > B BA PF +) (- AB B> B C IF ) F P > A) C I > BF B 9> PF> > B BA PF ( )(

  8. Slide 8: 3 F = A = 49M 6 BI

    08 ) - 3 F = A = 49M 6 = = BI - 4 29 I D =I 9 IA D 9D BADA 9B = F D = AD F9IA=DI 9AB= D :A B A 5 :8 A 65B8= 8 3 C5= 05 27 A8 3 C5= 05 27 A8 :A B A = 9 I M FI 1 1() 1 1() ( ( ( ( ( ( 1, % ( ( ( % ( % 5 :8 A 65B8= 8 15AC 5= 05 27 A8 15AC 5= 05 27 A8 0A B A = 9 I M FI 1 1 1 1 1 1() 1 1 1 1 1 1() ( ( (

  9. Slide 9: 7I:IA IA<:BB A DA A<:DI AD< : AD A6

    019(*( . 7I:IA IA<:BB A DA A<:DI AD< : AD A6 ( F A D 2 - 1-1 -- 2 - 1 - 3 B AD <IA D :IA 3 B AD <IA D :IA • - - *- * * ) ) ( ( (* 2: 2: 2: )* 2: 2: )* 2: )* FB:< 019(*( 5B:< 019(*( F :B ) 8 :I DI :D IA F ADI 0 8 DAD 7I 8 : 4D B: :I 2A : -

  10. Slide 10: A6 B :B6B : D 6 : 1 B ) B : A 6B6

    ,-5 ) A6 B :B6B : D 6 : 1 B ) B : A 6B6 08 A B H B D6 :B B 6 B D 6 :7 :B : B : A 02 ( 2 0 8D B H BD 6 : HB : B 6B : H 6 :6 6B : 7: 6H : A 8A E8 ) 6 : 6 666 : A: H7A B 0 0 A 1: 6B 6 ) 16 6 ) ( 08 A 08 A 1B 6 ) B B DD: H 02: 8202 3 A 19 2 A 3 28A8 3 /, , :6 6 : 6 : 6 1 B 6 B ,-5 ) : D : B 6 : D B :6 1

  11. Slide 11: 7JI D I A = I AI=I A D=MA =I= SM M JIB

    12 ) ) % = I AI=I A D=MA 1 = 91 1 1 8 1 1 /1 8 ) / 1 7JI D I A =I= SM M JIB M M JI J AI = . JI DM A AMAI A I 7=S = 33 9=I 3 A J ) 8 /8 1 ) 1 I0 . 8= A J I JI I0 9=BA S JB A A = IM PA S JJ D IJ )% MAPA A = PA MA A= JIM ( 12 ) ) I JI I0 ( (% 4 DA JPA AI JB 8= = 7=SJ 9 J A J I S, I = AI M DJ A A PA % 1

  12. Slide 12: A 6C 4 DD H H AL

    () A 6C H AL FCA AI 4 DD H F () A 6 F AF A I - HF H D A DFH I B I 1 ( H () H F I HAF I L HI H AF I F I L H A AF I F C D F A F HF A A I 6 I A ) DF C • (CC FA I LF H C F () • , I F I F AF D A DF A HAD • 2 H A C 0 F 4 FH F A F H I • , C C HF A C L CI M FM F L C I HF A FHD C L C I ( H A 4 FH FM H I C DD

  13. Slide 13: A D A 3 D C

    2 6 A DA3 3 3 2 - 3 D 6 B3D D C B E B3D DC 3C CE4 DD 6 D B E 3D BH 3 C BCD E DB C 1 3 6 3 363 3C 3 CDE6 C 3B 4 CE4 DD 6 2 2 3 2 3 3 3 2 - - -3 ,E D A B CC 3B C IC 6 C 3C 3 6 C B 3C C EB D BH 3B6C 3 3D BH C 3C C

  14. Slide 14: . )*) I AG H A B NE I, 0 0 HA E NA

    . )*) I AG H A B NE I, 0 0 HA E NA ABBA NM I EIBG HH NE I )() :1 6 : ( :2 )() :1 6 : )() EI M N NDA H ENS B ( ( NM I NDA 0 0 N - CAIA NA EI NDA 6:1 : : : 1 26: )() : 1 I 1 6 4 1 )() - 1 : 6:6: 6- IA AMM S B ENM AMMEIC 6:26: 0 0 6:2 A BN G IC 6- I I EIC - SEIC :1 2 EI EIC : 6 6:4 B HE . 6- G IC I I E

  15. Slide 15: 1: AC ) GC

    ( ( 6 CA 1: AC ) GC 5J G :G J C D 9 C G A9 , C C , C 6 D BADA 9AC A 0 : :9 ECA 5 E DD : : E 1 CD I A9 ) 6 A (C A 1 CD I 2 00 1 0 : CAD :G:9 IC G::E ( ( DD 9 A C C C 5A AC , C DBA D D 1 E :G : 65 6 / D 9 CD 6 A 5GEC DE: 9 G C6 6 C A B A6 C6 6 C 2 CD: 65 CE D : I:E :E( )A 5 A C 6 6 BA 5 ACD 65 1 GE GC

  16. Slide 16: I M H

    12 /, I M H D I 533 H MB H AB CBI A R -6 3 6 8 3B 6 B 12 /, 1I 84 796 6H D ID 4 R 0 D D3 4 R+ 4 R- 4 R 4 R 4 R - 4 R / 4 R (, 4 R, 1 6 9 1 9 6 9 1 6 H 6IP M I C PB D3 6 D3 6 0 D3 6 0 0 169 5 6 0 36 4 + , ( B + B <B B CBI 12 /, 1I 84 12 /, 1I 84 % 63 D6 B D3A ) H B%D 1 I ID R AM 6IC HH R 4 MB MBM ,

  17. Slide 17: 6A9 A8D 6 D 2BD6; A 7

    6A9 A8D 6 D 6 3 0 3 3 6 4 8 -. * 2BD6; A 7 -A 1 -. * -A 1 % 21 13 0 6 + 6 - DA A< 2 BD BI6D9 0A; 6 6 BD 6

  18. Slide 18: 2 E . / AFXNTSF KT NS 944 XM FU

    2 E . / AFXNTSF KT NS 944 XM FU 1 C D A CA CD D D D F A , ( C 7 BBCA AC A CA A C A 7 AC AF 6ST RT UT XT L X GT S :SK FR I RNH T S N TSR SX BX FX LN XMFX T HTR /B7 A ).0 A 0 B C UFXMTL S FSI STS UFXMTL SNH RT H KF T NRR S H MF XNTS% XM NRR ST UU N AC BC AFD C 7 H DAC D 7 4 SX F T NS MT X I K S FSI M

  19. Slide 19: A :9 9 1 1 1 5 1 26 1 1 1 2 ,1

    29 1 A 1 9 99 9 :9 1 31 1 59 1 1 4 1 65 5 6 4 1 4 1 4 1 1 2 9 1 1 1 5 1 26 1 1 1 2 ,1 A9 9 1: 9 9 :F3: 1: 1 A92 9 5 1 1 21 59 A9 9 1: A9 9 1: A9 9 1: 1 1 1 3 0 9 /A F 0 D1 :1 1A F 9 1

  20. Slide 20: 7BS J K IS C M

    7BS J K IS C M 0 : : 3 6 : B 9: H H: HA9 H :9 / FP R BI 4J IABA FI (& ) K F FI IB (& S CC B 1 KF FMFID 3 ,, CC B 1 KF , 0J A I DB BI 1 6 A ) 3 JIBR FM 5I J CJ IAB M 5) 4 && ()))( H 9 ) (,7 ME BM%A S FI (& F , B 6 BA 0C: 6 BA :69 B : FM 1 ME( 3 K JSBBM( L ,BBC: 6 : 6 , 23 ( 8JI KB FB FI 2 FI ; KKJ ;/

  21. Slide 21: A7A8 7 D: & %, 2 FO

    .8 7 % - 2: A7A8 7 D: & %, 2 FO & % 2 FO D DH FO FD D DN /H % %% 3C:D % % 8 0 /H % - % , 3C:D /H 6I D /H %- - % 3 :D , % 4: :A : % 5 4 HF % , %% & % FD D DN 3 H 8 0 , 9H E & & % / C 1 HA I DH % % & N DE E A D I H FO D HI DH AH %& FH C DE 7% & & . 6 DA A 5 D 6 I7D9 1A 7 7 D 0 :7 : %

  22. Slide 22: C D A GF H &B FF

    C D A GF H &B FF • . • & GF H D B B 2 F D B A • • • DE • A. . . • & A A D . . B D D F D • & &B D • DB EE H • 2 G FBD DE D - AG FGD A G F • . • , • . . , • . . -.C . • & A • 2 • & - • &.2 D FBD BGA D C D F BAE D B AF H D C F BD B . . C. GDA A FBD BI D E ,A FBD E E E

Abivax — Investor Presentation (April 2019) on 6ix